Clinical Concentrations of Thioridazine Kill Intracellular Multidrug-Resistant *Mycobacterium tuberculosis*

Diane Ordway,1 Miguel Viveiros,1 Clara Leandro,1 Rosário Bettencourt,1 Josefinha Almeida,1 Marta Martins,1 Jette E. Kristiansen,2 Joseph Molnar,3 and Leonard Amaral1*

Unit of Mycobacteriology, Instituto de Higiene e Medicina Tropical, Universidade Nova de Lisboa, 1349-008 Lisbon, Portugal1; Department of Clinical Microbiology, Sonderborg Sygehus, 6400 Sonderborg, Denmark2; and Institute of Medical Microbiology, Albert-Szent Gyorgyi School of Medicine, 6720 Szeged, Hungary3

Received 12 August 2002/Returned for modification 29 October 2002/Accepted 12 December 2002

The phenothiazines chlorpromazine (CPZ) and thioridazine (TZ) have equal in vitro activities against antibiotic-sensitive and -resistant *Mycobacterium tuberculosis*. These compounds have not been used as anti-*M. tuberculosis* agents because their in vitro activities take place at concentrations which are beyond those that are clinically achievable. In addition, chronic administration of CPZ produces frequent severe side effects. Because CPZ has been shown to enhance the killing of intracellular *M. tuberculosis* at concentrations that are clinically relevant, we have investigated whether TZ, a phenothiazine whose negative side effects are less frequent and serious than those associated with CPZ, kills *M. tuberculosis* organisms that have been phagocytosed by human macrophages, which have nominal killing activities against these bacteria. Both CPZ and TZ killed intracellular antibiotic-sensitive and -resistant *M. tuberculosis* organisms when they were used at concentrations in the medium well below those present in the plasma of patients treated with these agents. These concentrations in vitro were not toxic to the macrophage, nor did they affect in vitro cellular immune processes. TZ thus appears to be a serious candidate for the management of a freshly diagnosed infection of pulmonary tuberculosis or as an adjunct to conventional antituberculosis therapy if the patient originates from an area known to have a high prevalence of multidrug-resistant *M. tuberculosis* isolates. Nevertheless, we must await the outcomes of clinical trials to determine whether TZ itself may be safely and effectively used as an antituberculosis agent.

The in vitro activities of phenothiazines against *Mycobacterium tuberculosis* have been known for many decades (28, 29, 31). Since the introduction of the phenothiazine chlorpromazine (CPZ) in 1953 by Rhône-Poulenc (9), sporadic reports have indicated that CPZ has in vitro activity similar to those of other phenothiazines in vivo (15, 30, 24). Nevertheless, CPZ has not been considered for use in the management of pulmonary tuberculosis due to the severe side effects associated with its chronic use (25, 26) as well as the fact that the in vitro activity of this compound takes place at concentrations that are well beyond those that can be safely achieved in patients (3, 27, 28, 29, 31). However, in 1992, Crowle et al. (10) demonstrated that CPZ could inhibit the growth of *M. tuberculosis* that had been phagocytosed by human macrophages when CPZ was present in the medium at concentrations ranging from 0.23 to 3.6 mg/liter.

The ability of the macrophage to concentrate CPZ had previously been established (20, 23), and Crowle et al. (10) postulated that the intracellular killing activity of CPZ is due to this concentrating ability of the macrophage. At that time (the early 1990s) the problem of tuberculosis (TB) was not significant in most Western countries. Therefore, CPZ, which produces serious side effects, was not considered for use in the management of TB.

In the early 1990s, New York City became aware that its annual case load of TB had increased dramatically (13). Moreover, the increase was accompanied by a large number of *M. tuberculosis* isolates resistant to one or more commonly used antibiotics (13). Soon thereafter, similar observations were made in the major urban centers of Europe (7, 34). A 1997 World Health Organization report (38) demonstrated the worldwide frequency of both pulmonary TB and the antibiotic resistance of the causative organism, *M. tuberculosis*. By that time TB was seen as endemic in many parts of the world and epidemic in still others.

The antibiotic resistance of *M. tuberculosis* is attributed to many factors and will not be discussed here. Because the rates of resistance of *M. tuberculosis* to both isoniazid (INH) and rifampin (RIF) (multidrug resistance [MDR]), the two most effective anti-TB agents, were increasing at alarming rates, the American Thoracic Society and the Centers for Disease Control and Prevention issued guidelines for the therapy of newly diagnosed pulmonary TB (6). Nevertheless, in areas of the world such as Portugal, where the rate of resistance of *M. tuberculosis* to as many as four of the frontline drugs used to treat pulmonary TB exceeds 5% (37), the guidelines were not as effective as they proved to be in the United States (16). The need for new and effective anti-TB drugs is recognized (35), and it is this need which has spurred our interest in pursuing...
the question of whether another less toxic phenothiazine may be exploited as an anti-TB agent.

Thioridazine (TZ), a sister phenothiazine of CPZ used for the treatment of psychosis, is equal to CPZ with respect to its in vitro antimycobacterial properties (1, 4, 38). Because this compound is concentrated by human macrophages (10, 20, 23) and is active against intracellular Staphylococcus aureus, regardless of its susceptibility or resistance to methicillin (32), we have repeated the latter studies with M. tuberculosis in place of staphylococci. The results of this study provide strong direct evidence that TZ, a neuroleptic that is milder and less toxic than CPZ, kills intracellular M. tuberculosis isolates that are resistant to two or more antibiotics when the concentration of TZ in the medium approaches that in the plasma of a patient chronically managed with this compound.

MATERIALS AND METHODS

Materials. Balanced salt solution, phosphate-buffered saline, Hank’s balanced salt solution, Ficoll, and glutamine were purchased from Gibco, Paisley, United Kingdom. CPZ, TZ, paraformaldehyde, sodium dodecyl sulfate (SDS), Triton X-100, sodium azide, naphthol blue-black, and trypan blue were purchased from Sigma Aldrich Quimica SA, Madrid, Spain. Middlebrook 7H11 solid medium was purchased from Difco, Detroit, Mich. The materials used for antibiotic susceptibility testing of M. tuberculosis with the BACTEC 460-TB system were purchased from Becton Dickinson Diagnostic Instrument Systems, Sparks, Md., and prepared according to the recommendations of the manufacturer. Microwell tissue culture plates were purchased from Nalgene, Rochester, N.Y. All phenothiazine solutions were prepared in distilled, sterile water on the day of the experiment.

Bacterial strains. M. tuberculosis H37Rv (ATCC 27294), which is susceptible to RIF, INH, streptomycin (SM), and ethambutol (EMB), served as the absolute control; and five clinical strains (strains A to E) that have been maintained in the Unit of Mycobacteriology, Instituto de Higiene e Medicina Tropical, Universidade Nova de Lisboa, Lisbon, Portugal, and characterized for their susceptibility and resistance to the antibiotics listed above with the BACTEC 460-TB system were also used (1, 8, 36). Strains A and B are susceptible to all four drugs. Strain C is resistant to all four drugs. Strains D and E, besides being resistant to INH and RIF, are also resistant to SM. Strain D was isolated from a patient involved in an outbreak caused by a highly virulent MDR M. tuberculosis strain (cluster A or cluster Lisbon) in a Lisbon Prison Hospital in 1997 and has been typed by IS6110-based restriction fragment length polymorphism analysis as a member of this cluster (33).

Methods. (i) Determination of MICs and MBCs. The MICs of CPZ and TZ were determined individually by the BACTEC 460-TB method as described previously (1, 8, 36). Briefly, carefully prepared stock solutions containing various amounts of each compound were separately prepared in 12B BACTEC 460 medium, and 0.1-ml aliquots of each were added to 12B BACTEC 460 vials. The final concentrations of CPZ and TZ in the BACTEC 460 vials were 0, 1, 5, 10, 15, 20, 30, 40, 50, and 60 mg/liter. Each vial received 0.1 ml of 12B BACTEC 460 vials; other concentrations that ranged from 0 to 5.0 mg/liter were added to the wells; other wells received 0.01 ml of approximately 106 live M. tuberculosis organisms (H37Rv [ATCC 27294]). The microplates were incubated at 37°C for 3 days, and the numbers of CFU present on the plates were subjected to counting of the numbers of CFU in order to determine the efficiency of phagocytosis. A third wash was performed, and the washings were subjected to counting of the numbers of CFU in order to determine the completeness of phagocytosed bacteria. The cultures of adhered cells-phagocytosed bacteria were incubated at 37°C for 0 to 3 days and lysed by the addition of 1.0 ml of 0.01% SDS at the end of each incubation period. Aliquots of 0.1 ml of the lysed cultures were serially diluted with saline to 10−5, 1.0-ml aliquots of each dilution were plated onto Middlebrook 7H11 solid medium, the plates were incubated at 37°C for 4 weeks, and the colonies were counted (CFU determination) (36).

(ii) Effects of CPZ and TZ on killing activities of THP-1 and PBMDMs. A total of 107 macrophages in the microplate wells were preincubated with either CPZ or TZ at nontoxic concentrations of 0.01 and 0.1 mg/liter for 1 h, and M. tuberculosis was then added to the cultures at a ratio of 1 CFU/macrophiage for 30 min. The addition of these concentrations of CPZ or TZ to a macrophage culture prior to infection with S. aureus does not significantly affect the ability of the macrophage to phagocytose the bacteria (32). These cultures were then washed with medium in order to remove any phagocytosed bacteria; fresh medium was added; and the cultures were incubated for 0, 1, 2, and 3 days at 37°C. At the end of each culture period, 0.01% SDS was added and the number of viable bacterial cells present in the supernatants of the lysed cultures was determined by counting of the numbers of CFU. All experiments were conducted in triplicate and were performed at least twice.

Statistical analysis. All data obtained were subjected to nonparametric statistical evaluation with the aid of the Mann-Whitney U test.

Ethical permission. The blood samples used in this study were obtained from healthy donors in Portugal after the donors granted written permission. This study was approved by the Ethics Committee of the Hospital Egas Moniz, Lisbon, Portugal, and the Instituto de Higiene e Medicina Tropical.
The individual MICs of RIF, INH, SM, EMB, CPZ and TZ, were determined by the BACTEC 460-TB method, as described previously (1, 8, 36). Stock solutions containing various amounts of each compound were freshly prepared in BACTEC 460 medium, and 0.1-ml aliquots of each solution were added to BACTEC 460 vials. The final concentrations of CPZ and TZ in the BACTEC 460 vials were 0, 1, 5, 10, 15, 20, 30, 40, 50, and 60 mg/liter. A total of 0.1 ml of BACTEC 460 medium containing an adjusted concentration of mycobacteria corresponding to approximately 10^5 to 10^6 CFU was added to each vial (36). The MICs of CPZ and TZ were determined by extending the MIC curves well beyond each MIC, and 10-μl aliquots of the 10-ml cultures at zero time and those after 30 days that showed no evidence of growth in the BACTEC 12B vials were subjected to counting of the numbers of CFU (36). The MIC and MBC determinations were repeated three times, and the values obtained did not differ significantly. Strains ATCC 27294, A, and B are susceptible to INH, RIF, SM, and EMB. Strain C is resistant to all four drugs. Strains D and E, besides being resistant to INH and RIF, are also resistant to SM.

**Table 1.** MICs and MBCs of CPZ and TZ for antibiotic-sensitive and MDR strains of *M. tuberculosis*.

<table>
<thead>
<tr>
<th>Drug</th>
<th>ATCC 27294</th>
<th>A</th>
<th>B</th>
<th>C</th>
<th>D</th>
<th>E</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>MIC (μg/ml)</td>
<td>MBC (μg/ml)</td>
<td>MIC (μg/ml)</td>
<td>MBC (μg/ml)</td>
<td>MIC (μg/ml)</td>
<td>MBC (μg/ml)</td>
</tr>
<tr>
<td>CPZ</td>
<td>10</td>
<td>20</td>
<td>10</td>
<td>20</td>
<td>30</td>
<td>40</td>
</tr>
<tr>
<td>TZ</td>
<td>15</td>
<td>30</td>
<td>15</td>
<td>30</td>
<td>30</td>
<td>50</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*The individual MICs of RIF, INH, SM, EMB, CPZ and TZ, were determined by the BACTEC 460-TB method, as described previously (1, 8, 36). Stock solutions containing various amounts of each compound were freshly prepared in BACTEC 460 medium, and 0.1-ml aliquots of each solution were added to BACTEC 460 vials. The final concentrations of CPZ and TZ in the BACTEC 460 vials were 0, 1, 5, 10, 15, 20, 30, 40, 50, and 60 mg/liter. A total of 0.1 ml of BACTEC 460 medium containing an adjusted concentration of mycobacteria corresponding to approximately 10^5 to 10^6 CFU was added to each vial (36). The MICs of CPZ and TZ were determined by extending the MIC curves well beyond each MIC, and 10-μl aliquots of the 10-ml cultures at zero time and those after 30 days that showed no evidence of growth in the BACTEC 12B vials were subjected to counting of the numbers of CFU (36). The MIC and MBC determinations were repeated three times, and the values obtained did not differ significantly. Strains ATCC 27294, A, and B are susceptible to INH, RIF, SM, and EMB. Strain C is resistant to all four drugs. Strains D and E, besides being resistant to INH and RIF, are also resistant to SM.*

**RESULTS**

MICs and MBCs of CPZ and TZ for antibiotic-susceptible and MDR *M. tuberculosis* strains. The average MICs and MBCs of CPZ and TZ for three antibiotic-susceptible strains (including strain ATCC 27294) and three antibiotic-resistant *M. tuberculosis* strains are summarized in Table 1. Briefly, the MBCs of CPZ and TZ were significantly greater than the respective MICs for antibiotic-susceptible and -resistant strains of *M. tuberculosis*. The activities of TZ against each of the strains were greater than those of CPZ. Lastly, MDR *M. tuberculosis* strains were significantly more resistant to the actions of CPZ and TZ than the antibiotic-susceptible strains were. It is noteworthy that because the MICs and MBCs were not determined by the broth dilution method and, indeed, were the precise concentrations used against a constant standardized inoculum, the differences noted above are deemed significant.

Toxicities of CPZ and TZ against THP-1 cells, PBMDMs, and subsets of the Ficoll preparation. The potential toxicities of CPZ or TZ against THP-1 cells and PBMDMs were evaluated by three distinct methods in a previous study, and 50% of the full toxicity was shown to take place at concentrations that exceeded 3.0 mg/liter (32). Similar results were obtained in this study (data not shown). The toxicities of the phenothiazines at concentrations below those anticipated to be present in the plasma of a patient treated with 600 mg of either phenothiazine per day (5) against subsets of the Ficoll monocyte preparation were examined in the present study. Briefly, as shown in Fig. 1, the concentrations of CPZ and TZ that correspond to those readily evident during initial therapy of a patient, i.e., 0.1 mg/liter, had a nominal effect on annexin V binding, determination of which is the method for choice of the demonstration of apoptosis (32). The percentage of annexin V binding indicative of early apoptosis is 10% for alpha-beta and gamma-delta T cells and CD14+ macrophages (32). The data presented in Fig. 1 also show that the presence of live mycobacteria during a culture period of 3 days did not increase the percent annexin V binding by the various monocyte subsets evaluated. Significant toxicity against THP-1 cells, PBMDMs, or lymphocytes was evident with concentrations of either phenothiazine that exceeded 0.5 mg/liter (data not shown).

Effects of CPZ and TZ on killing of *M. tuberculosis* phago-
complete killing took place by the end of the third day postinfection (Fig. 3A and B). Lower concentrations of these phenothiazines were ineffective, and the rates of survival of all intracellular mycobacterial strains were indistinguishable from those for their controls (Fig. 3A and 3B). Although the results presented above were obtained by use of PBMDMs, similar results were obtained by use of the THP-1 macrophage cell line (data not shown).

DISCUSSION

The toxicity associated with chronic use of CPZ is well known (5, 25, 26). In addition, CPZ has been shown to affect the activities of a variety of T lymphocytes in vitro (17, 19, 21), although these inhibitory effects require concentrations of CPZ which are beyond those clinically relevant (i.e., in excess of 1 mg/liter) or fairly close to the highest concentration of CPZ in plasma that might result from its aggressive use (>0.5 mg/liter). Our previous study (32) and the present study show that an in vitro concentration of 0.1 mg of either CPZ or TZ per liter, which is equivalent to that anticipated to be present in the plasma of a patient treated with either phenothiazine, has no significant toxicity against macrophages or alpha-beta TCR⁺, gamma-delta TCR⁺, or CD14⁺ macrophages.

Concentrations of either CPZ or TZ that are well below their range for toxicity against human macrophages, THP-1 macrophages, or subsets of T lymphocytes in vitro, as shown in this and other studies (32), were shown in the present study to enhance the killing of M. tuberculosis strains that are phagocytosed by either PBMDMs or THP-1 cells. Complete killing is evident by the end of 3 days postinfection at a minimum concentration of 0.1 mg/liter, regardless of the antibiotic susceptibility of the strain. When similar M. tuberculosis strains are exposed to concentrations of CPZ or TZ in vitro, the minimum concentration of either CPZ or TZ required to completely inhibit growth ranges from 8 to over 30 mg/liter (4, 8, 10, 37). The minimum in vitro concentration of either phenothiazine required for complete killing (MBC) in the absence of the macrophage, as shown in our study, ranges from 20 to 50 mg/liter and is similar to that reported previously (4). Because these phenothiazines are concentrated by macrophages (2), cells that have little killing actions of their own (22, 32), it is likely that the concentration of either phenothiazine required to kill M. tuberculosis cells in vitro is achieved because the macrophage is able not only to concentrate the compounds but also to make these compounds available in an active form to the cytoplasmic structure of the macrophage that houses the entrapped phagocytosed bacterium (2). Nevertheless, it is also possible that the lytic action of the macrophage lysosomal apparatus, which is apparently weak, might be sufficiently effective to affect the integrity of the bacterium’s cell wall. This weakened cell wall might be more permeable for the penetration of these compounds, which eventually intercalate between the nucleic acid base pairs of the bacterium’s DNA, where DNA-dependent functions may be affected (12). Regardless of the cause of killing, in vitro resistance of MDR M. tuberculosis to either CPZ or TZ, as opposed to that of the antibiotic-susceptible strains, is not evident after the MDR M. tuberculosis strain is phagocytosed by macrophages that have previously been loaded with either CPZ or TZ.

The demonstration that clinically relevant concentrations of either CPZ or TZ that are neither toxic in vitro to the macrophage nor inhibitory of T-cell activity in vitro kill phagocytosed mycobacteria supports their use in the management of intra-

FIG. 2. Average killing activities of human PBMDMs against M. tuberculosis ATCC 27294 (ATCC), two antibiotic-susceptible strains (strains A and B [TB]), and three MDR M. tuberculosis strains (strains C, D, and E; resistant at least to RIF and INH [MDRTB]). The killing activities against the strains used were not significantly different.

FIG. 3. Average killing activities of human PBMDMs against three MDR M. tuberculosis strains (resistant to RIF and INH) (MDRTB) and three antibiotic-susceptible M. tuberculosis strains (TB) including strain ATCC 27294 when either CPZ (A) or TZ (B) was present in the medium at concentrations of 0.01 and 0.1 mg/liter. The control value is the average numbers of CFU for cultures of all six strains to which no phenothiazine was added, inasmuch as the CFU did not differ appreciably between strains.
cellular *M. tuberculosis* infections. TZ has significantly fewer serious side effects than CPZ (5), making the use of TZ use as an anti-TB agent far more attractive than the use of CPZ. However, its use is not without some risk, inasmuch as almost twice as many sudden deaths due to cardiac failure take place in patients managed with TZ compared to the number of deaths from such causes in the general population (18). Although TZ may induce episodes of torsade de points that result in sudden death, there are only 10 to 15 such events in 10,000 person-years of observation (18). Regardless, careful monitoring of cardiac function during TZ management is strongly recommended.

Admittedly, the use of TZ for the management of an active pulmonary TB infection caused by antibiotic-susceptible *M. tuberculosis* strains provides no advantage over the use of CPZ. Management of a cavitary pulmonary infection with concomitant induction of cellular immune responses by tetra-macrocyte and acytate pendant arms. Res. Microbiol. 152:569–576.


35. Schraufnagel, D. E. 1999. Tuberculosis treatment for the beginning of the

